Drug intelligence / Profile preview

FH-STEAP1 IL-18 CAR T cells

Development stage: Phase 1
Lead developer: PromiCell Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

FH-STEAP1 IL-18 CAR T cells (also known as PRO CAR-202) is an investigational, autologous, genetically engineered chimeric antigen receptor (CAR) T-cell therapy developed by Fred Hutchinson Cancer Center and licensed to PromiCell. The therapy targets Six-transmembrane epithelial antigen of the prostate 1 (STEAP1), a cell surface antigen highly expressed in metastatic castration-resistant prostate cancer (mCRPC) and Ewing sarcoma. To overcome the immunosuppressive solid tumor microenvironment, these CAR T cells are 'armored' to secrete interleukin-18 (IL-18), a pro-inflammatory cytokine that enhances T-cell persistence, proliferation, and anti-tumor activity. FH-STEAP1 IL-18 CAR T cells are being evaluated in a Phase 1 clinical trial (NCT07803653) for patients with mCRPC following lymphodepleting chemotherapy.

Other names: FH-STEAP1 IL-18 CAR TFH-STEAP-1 IL-18 CAR TFH-STEAP 1 IL-18 CAR TIL-18 Armored STEAP1 CAR TIL18 Armored STEAP1 CAR TIL 18 Armored STEAP1 CAR TIL-18 armored STEAP1 CAR T cellsIL18 armored STEAP1 CAR T cellsIL 18 armored STEAP1 CAR T cells

Targets

IL-18R (Interleukin-18 receptor complex)STEAP1 (Six-transmembrane epithelial antigen of prostate 1)

Beyond the preview

Go deeper on FH-STEAP1 IL-18 CAR T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FH-STEAP1 IL-18 CAR T cells.

Explore the full profile